AbCellera Biologics Inc. (NASDAQ:ABCL) finished Friday with a subtraction of -$0.33 to close at $15.97, a downside of -2.02 percent. An average of 1,000,560 shares of common stock have been traded in the last five days. There was a gain of $0.44 in the past week. The last 20 days have seen an average of 1,944,835 shares traded, while the 50-day average volume stands at 2,681,216.
ABCL stock has decreased by -24.49% in the last month. The company shares reached their 1-month lowest point of $14.78 on 10/12/21. Shares of the company touched a low of $14.51 and a high of $71.91 in 52 weeks. It has reached a new high 10 times so far this year and lost -60.31% or -$24.27 in price. In spite of this, the price is down -77.79% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
52 days have passed since AbCellera Biologics Inc. (ABCL) last reported insider trading activity. HAMER JOHN, who is Director, most recently acquired $137,351 shares at $16.93 per share on Sep 01. In this transaction, the insider spent $2,325,352. Director, HAMER JOHN, disposed of 162,649 shares at a price of $16.95 on Aug 31. The insider now owns more than $2,756,901 worth of shares. Prior to that, Director Hayden Michael R went on to Sale 100,000 shares at $25.50 each on Jun 22. An amount of $2,550,000 was transacted.
AbCellera Biologics Inc. (ABCL) has a trailing price-to-earnings (P/E) ratio of 21.58, which compares with the 34.65 for the broader industry and 33.43 for the sector. In the last five years, AbCellera Biologics Inc.’s PE ratio has ranged between 167.83 and 22.50. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 10.19, the price-to-book (PB) ratio at 4.49.
The quick ratio of AbCellera Biologics Inc. for the three months ended June 29 was 12.40, and the current ratio was 12.40, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29. AbCellera Biologics Inc.’s EBITDA margin for the year ending June 29 is 80.82%.
The company posted a net income of -$2.32 million in the quarter, while revenues of $117.22 million were grew 100.0%. The analyst consensus anticipated AbCellera Biologics Inc.’s latest quarter earnings to come in at $0.08 per share, but it turned out to be -$0.01, a -112.50% surprise. At the end of the quarter ending June 29, AbCellera Biologics Inc.’s stock balance sheet showed total debt was $34.9 million.
From a technical analysis perspective, let’s take a brief look at AbCellera Biologics Inc. (ABCL) price momentum. RSI 9-day as of the close on 22 October was 43.71%, suggesting the stock is Neutral, with historical volatility in this time frame at 34.99%.
As of today, ABCL’s price is $15.91 +2.83% or $0.44 from its 5-day moving average. ABCL is currently trading -24.49% lower than its 20-day SMA and -40.57% lower than its 100-day SMA. However, the stock’s current price level is +5.13% above the SMA50 and -59.38% below the SMA200.
The stochastic %K and %D were 50.78% and 36.38%, respectively, and the average true range (ATR) was 0.81. With the 14-day stochastic at 56.67% and the average true range at 0.92, the RSI (14) stands at 42.95%. The stock has reached 0.37 on the 9-day MACD Oscillator while the 14-day reading was at 0.41.
SVB Leerink launched coverage on AbCellera Biologics Inc. (NASDAQ: ABCL) in its analyst report released on January 05, 2021. The firm assigned the stock a an Outperform rating. The consensus rating for AbCellera Biologics Inc. (ABCL) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell ABCL, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 5 others rate it as a “buy”.
What is ABCL’s price target for the next 12 months?
Analysts predict a range of price targets between $25.00 and $55.00, with a median target of $49.00. Taking a look at these predictions, the average price target given by analysts for AbCellera Biologics Inc. (ABCL) stock is $45.40.